Cargando…

Immunogenicity evaluation of recombinant Lactobacillus casei W56 expressing bovine viral diarrhea virus E2 protein in conjunction with cholera toxin B subunit as an adjuvant

BACKGROUND: Bovine viral diarrhea virus (BVDV) is one of the main causes of infectious diseases in cattle and causes large financial losses to the cattle industry worldwide. In this study, Lactobacillus casei strain W56 (Lc W56) was used as antigen deliver carrier to construct a recombinant Lactobac...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Shuo, Huang, Xinning, Li, Hua, Zheng, Dianzhong, Wang, Li, Qiao, Xinyuan, Jiang, Yanping, Cui, Wen, Tang, Lijie, Li, Yijing, Xu, Yigang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527787/
https://www.ncbi.nlm.nih.gov/pubmed/33004035
http://dx.doi.org/10.1186/s12934-020-01449-3
_version_ 1783589131739201536
author Jia, Shuo
Huang, Xinning
Li, Hua
Zheng, Dianzhong
Wang, Li
Qiao, Xinyuan
Jiang, Yanping
Cui, Wen
Tang, Lijie
Li, Yijing
Xu, Yigang
author_facet Jia, Shuo
Huang, Xinning
Li, Hua
Zheng, Dianzhong
Wang, Li
Qiao, Xinyuan
Jiang, Yanping
Cui, Wen
Tang, Lijie
Li, Yijing
Xu, Yigang
author_sort Jia, Shuo
collection PubMed
description BACKGROUND: Bovine viral diarrhea virus (BVDV) is one of the main causes of infectious diseases in cattle and causes large financial losses to the cattle industry worldwide. In this study, Lactobacillus casei strain W56 (Lc W56) was used as antigen deliver carrier to construct a recombinant Lactobacillus vaccine pPG-E2-ctxB/Lc W56 constitutively expressing BVDV E2 protein fused with cholera toxin B subunit (ctxB) as an adjuvant, and its immunogenicity against BVDV infection in mice model by oral route was explored. RESULTS: Our results suggested that pPG-E2-ctxB/Lc W56 can effectively activate dendritic cells (DCs) in the Peyer’s patches, up-regulate the expression of Bcl-6, and promote T-follicular helper (Tfh) cells differentiation, as well as enhance B lymphocyte proliferation and promote them differentiate into specific IgA-secreting plasma cells, secreting anti-E2 mucosal sIgA antibody with BVDV-neutralizing activity. Moreover, significant levels (p < 0.01) of BVDV-neutralizing antigen-specific serum antibodies were induced in the pPG-E2-ctxB/LC W56 group post-vaccination. The recombinant Lactobacillus vaccine can induce cellular immune responses, and significant levels (p < 0.01) of Th1-associated cytokines (IL-2, IL-12, and IFN-γ), Th2-associated cytokines (IL-4, IL-10) and Th17-associated cytokine (IL-17) were determined in the serum of vaccinated mice. Significantly, the recombinant Lactobacillus vaccine provides immune protection against BVDV infection, which can be cleared effectively by the vaccine post-challenge in orally vaccinated animals. CONCLUSIONS: The genetically engineered Lactobacillus vaccine constructed in this study is immunogenic in mice and can induce mucosal, humoral, and cellular immune responses, providing effective anti-BVDV immune protection. It thus represents a promising strategy for vaccine development against BVDV.
format Online
Article
Text
id pubmed-7527787
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-75277872020-10-01 Immunogenicity evaluation of recombinant Lactobacillus casei W56 expressing bovine viral diarrhea virus E2 protein in conjunction with cholera toxin B subunit as an adjuvant Jia, Shuo Huang, Xinning Li, Hua Zheng, Dianzhong Wang, Li Qiao, Xinyuan Jiang, Yanping Cui, Wen Tang, Lijie Li, Yijing Xu, Yigang Microb Cell Fact Research BACKGROUND: Bovine viral diarrhea virus (BVDV) is one of the main causes of infectious diseases in cattle and causes large financial losses to the cattle industry worldwide. In this study, Lactobacillus casei strain W56 (Lc W56) was used as antigen deliver carrier to construct a recombinant Lactobacillus vaccine pPG-E2-ctxB/Lc W56 constitutively expressing BVDV E2 protein fused with cholera toxin B subunit (ctxB) as an adjuvant, and its immunogenicity against BVDV infection in mice model by oral route was explored. RESULTS: Our results suggested that pPG-E2-ctxB/Lc W56 can effectively activate dendritic cells (DCs) in the Peyer’s patches, up-regulate the expression of Bcl-6, and promote T-follicular helper (Tfh) cells differentiation, as well as enhance B lymphocyte proliferation and promote them differentiate into specific IgA-secreting plasma cells, secreting anti-E2 mucosal sIgA antibody with BVDV-neutralizing activity. Moreover, significant levels (p < 0.01) of BVDV-neutralizing antigen-specific serum antibodies were induced in the pPG-E2-ctxB/LC W56 group post-vaccination. The recombinant Lactobacillus vaccine can induce cellular immune responses, and significant levels (p < 0.01) of Th1-associated cytokines (IL-2, IL-12, and IFN-γ), Th2-associated cytokines (IL-4, IL-10) and Th17-associated cytokine (IL-17) were determined in the serum of vaccinated mice. Significantly, the recombinant Lactobacillus vaccine provides immune protection against BVDV infection, which can be cleared effectively by the vaccine post-challenge in orally vaccinated animals. CONCLUSIONS: The genetically engineered Lactobacillus vaccine constructed in this study is immunogenic in mice and can induce mucosal, humoral, and cellular immune responses, providing effective anti-BVDV immune protection. It thus represents a promising strategy for vaccine development against BVDV. BioMed Central 2020-10-01 /pmc/articles/PMC7527787/ /pubmed/33004035 http://dx.doi.org/10.1186/s12934-020-01449-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Jia, Shuo
Huang, Xinning
Li, Hua
Zheng, Dianzhong
Wang, Li
Qiao, Xinyuan
Jiang, Yanping
Cui, Wen
Tang, Lijie
Li, Yijing
Xu, Yigang
Immunogenicity evaluation of recombinant Lactobacillus casei W56 expressing bovine viral diarrhea virus E2 protein in conjunction with cholera toxin B subunit as an adjuvant
title Immunogenicity evaluation of recombinant Lactobacillus casei W56 expressing bovine viral diarrhea virus E2 protein in conjunction with cholera toxin B subunit as an adjuvant
title_full Immunogenicity evaluation of recombinant Lactobacillus casei W56 expressing bovine viral diarrhea virus E2 protein in conjunction with cholera toxin B subunit as an adjuvant
title_fullStr Immunogenicity evaluation of recombinant Lactobacillus casei W56 expressing bovine viral diarrhea virus E2 protein in conjunction with cholera toxin B subunit as an adjuvant
title_full_unstemmed Immunogenicity evaluation of recombinant Lactobacillus casei W56 expressing bovine viral diarrhea virus E2 protein in conjunction with cholera toxin B subunit as an adjuvant
title_short Immunogenicity evaluation of recombinant Lactobacillus casei W56 expressing bovine viral diarrhea virus E2 protein in conjunction with cholera toxin B subunit as an adjuvant
title_sort immunogenicity evaluation of recombinant lactobacillus casei w56 expressing bovine viral diarrhea virus e2 protein in conjunction with cholera toxin b subunit as an adjuvant
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527787/
https://www.ncbi.nlm.nih.gov/pubmed/33004035
http://dx.doi.org/10.1186/s12934-020-01449-3
work_keys_str_mv AT jiashuo immunogenicityevaluationofrecombinantlactobacilluscaseiw56expressingbovineviraldiarrheaviruse2proteininconjunctionwithcholeratoxinbsubunitasanadjuvant
AT huangxinning immunogenicityevaluationofrecombinantlactobacilluscaseiw56expressingbovineviraldiarrheaviruse2proteininconjunctionwithcholeratoxinbsubunitasanadjuvant
AT lihua immunogenicityevaluationofrecombinantlactobacilluscaseiw56expressingbovineviraldiarrheaviruse2proteininconjunctionwithcholeratoxinbsubunitasanadjuvant
AT zhengdianzhong immunogenicityevaluationofrecombinantlactobacilluscaseiw56expressingbovineviraldiarrheaviruse2proteininconjunctionwithcholeratoxinbsubunitasanadjuvant
AT wangli immunogenicityevaluationofrecombinantlactobacilluscaseiw56expressingbovineviraldiarrheaviruse2proteininconjunctionwithcholeratoxinbsubunitasanadjuvant
AT qiaoxinyuan immunogenicityevaluationofrecombinantlactobacilluscaseiw56expressingbovineviraldiarrheaviruse2proteininconjunctionwithcholeratoxinbsubunitasanadjuvant
AT jiangyanping immunogenicityevaluationofrecombinantlactobacilluscaseiw56expressingbovineviraldiarrheaviruse2proteininconjunctionwithcholeratoxinbsubunitasanadjuvant
AT cuiwen immunogenicityevaluationofrecombinantlactobacilluscaseiw56expressingbovineviraldiarrheaviruse2proteininconjunctionwithcholeratoxinbsubunitasanadjuvant
AT tanglijie immunogenicityevaluationofrecombinantlactobacilluscaseiw56expressingbovineviraldiarrheaviruse2proteininconjunctionwithcholeratoxinbsubunitasanadjuvant
AT liyijing immunogenicityevaluationofrecombinantlactobacilluscaseiw56expressingbovineviraldiarrheaviruse2proteininconjunctionwithcholeratoxinbsubunitasanadjuvant
AT xuyigang immunogenicityevaluationofrecombinantlactobacilluscaseiw56expressingbovineviraldiarrheaviruse2proteininconjunctionwithcholeratoxinbsubunitasanadjuvant